Karyopharm Reports First Quarter 2022 Financial Results and ...

Net loss: Karyopharm reported a net loss of $41.4 million, or $0.53 per share, for the first quarter of 2022, compared to a net loss of $57.4 ...

Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from ...

Karyopharm Reports First Quarter 2023 Financial Results and ...

Total demand1 growth driven by sales growth in the community compared to the first quarter of 2022, which contributed to about 70% of revenues ...

Press Releases - Investor Relations | Karyopharm Therapeutics

May 2, 2022. Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Apr 28, 2022. Karyopharm to Report First Quarter 2022 ...

Karyopharm to Report First Quarter 2022 Financial Results on May 5 ...

NEWTON, Mass., April 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer ...

Press Releases - Investor Relations | Karyopharm Therapeutics

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – – ...

Press Releases - Investor Relations | Karyopharm Therapeutics

– Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Third ...

Press Releases - Investor Relations | Karyopharm Therapeutics

May 5, 2022. Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress. – Achieved First Quarter 2022 Net Revenues of ...

Karyopharm Reports First Quarter 2023 Financial Results and ...

Achieved U.S. net product revenue for the first quarter of 2023 of $28.3 million, consistent with U.S. net product revenue in the first quarter ...

Karyopharm Reports First Quarter 2023 Financial Results and ...

Total demand1 growth driven by sales growth in the community compared to the first quarter of 2022, which contributed to about 70% of revenues in the first ...

Karyopharm to Report First Quarter 2024 Financial Results on May 8 ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it ...

First Quarter 2024 Financial Results & Business Update

XPOVIO® (selinexor) and NEXPOVIO® (selinexor) are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this ...

EX-99.1 - SEC.gov

Karyopharm Reports Third Quarter 2020 Financial Results and. Highlights Recent Company Progress. — Phase 3 SEAL Study Meets Primary Endpoint with ...

KPTI / Karyopharm Therapeutics Inc. - SEC Filings, Annual Report ...

Press Releases (Most Recent) ; 2022-08-04, Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Second ...

Legend Biotech Reports First Quarter 2022 Financial Results and ...

Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights · $34.9 million caused by changes in the fair value of a warrant that Legend ...

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial ...

SG&A expenses: SG&A expenses for the fourth quarter of 2023 were $30.7 million , compared to $34.6 million for the fourth quarter of 2022. SG&A ...

siendo - Cancer Trial Results

PRNewswire 2021 - Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress open_in_new ... '...During the first quarter of ...

Karyopharm Reports Third Quarter 2024 Financial Results and ...

Net product revenue: Net product revenue for the third quarter of 2024 was $29.5 million, compared to $30.2 million for the third quarter of ...

EX-99.1 - Yahoo Finance

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress. – ... revenue in the third quarter of 2022. •. Net XPOVIO ...

bluebird bio Reports Fourth Quarter and Full Year 2022 Financial ...

This runway includes approximately $45 million of restricted cash, which is currently unavailable for use. Please see our Annual Report filed on ...